以内镜下愈合为治疗目标的溃疡性结肠炎患者组织学缓解的预测因素与结局
本回顾性队列研究纳入411例活动性溃疡性结肠炎患者,治疗目标为内镜下愈合(改良Mayo内镜评分0或1)。270例达到内镜下愈合,其中55%同时达到组织学缓解;最终内镜评估时内镜愈合深度是组织学缓解的唯一独立决定因素(改良Mayo内镜评分0 vs 1:OR 0.31,95%CI 0.18-0.52)。中位随访28个月,组织学缓解与较低的临床复发风险(1年累积风险18.7% vs 29.5%;调整HR 0.56,95%CI 0.37-0.85)和较低的住院风险(HR 0.44,95%CI 0.20-0.94)相关,其增量获益仅在改良Mayo内镜评分1的患者中观察到。
要点
- 以改良Mayo内镜评分0或1为治疗目标时,55%达到内镜下愈合的患者同时达到组织学缓解。
- 最终内镜评估时改良Mayo内镜评分0 vs 1与组织学缓解独立相关(OR 0.31,95%CI 0.18-0.52)。
- 组织学缓解与较低临床复发和住院风险相关,增量获益仅见于改良Mayo内镜评分1的患者。
核心结论
- 在以达到内镜下愈合为治疗目标的活动性溃疡性结肠炎患者中,55%同时达到组织学缓解。
- 组织学缓解,尤其在达到改良Mayo内镜评分1的患者中,与较好的结局相关。
- 以组织学缓解而非内镜下愈合为治疗目标需前瞻性评估。
研究设计与样本
- 回顾性队列研究,纳入411例活动性溃疡性结肠炎成年患者(改良Mayo内镜评分2或3),治疗经过迭代优化以达到内镜下愈合。
- 采用Cox比例风险分析识别达到组织学缓解的预测因素及组织学缓解 vs 持续组织学活动的结局(症状性复发风险、溃疡性结肠炎相关住院和/或手术)。
主要发现
- 411例临床活动性溃疡性结肠炎患者中,270例达到内镜下愈合;270例中55%同时达到组织学缓解。
- 最终内镜评估时内镜愈合深度是组织学缓解的唯一独立决定因素(改良Mayo内镜评分0 vs 1:OR 0.31,95%CI 0.18-0.52)。
- 随访28个月,组织学缓解与较低的临床复发风险相关(1年累积风险18.7% vs 29.5%;调整HR 0.56,95%CI 0.37-0.85)。
- 组织学缓解与较低的住院风险相关(HR 0.44,95%CI 0.20-0.94)。
- 组织学缓解的增量获益仅在达到改良Mayo内镜评分1的患者中观察到,在改良Mayo内镜评分0的患者中未观察到。
关键数值与推荐
- 组织学缓解的独立决定因素:改良Mayo内镜评分0 vs 1的OR为0.31(95%CI 0.18-0.52)。
- 临床复发1年累积风险:组织学缓解组18.7% vs 持续组织学活动组29.5%,调整HR 0.56(95%CI 0.37-0.85)。
- 住院风险:HR 0.44(95%CI 0.20-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical remission is the recommended treatment target in ulcerative colitis. The predictors and outcomes of achieving histologic remission within a treat-to-target paradigm are not well established. AIM: To evaluate the predictors and outcomes of achieving histologic remission in patients with ulcerative colitis treated-to-target of endoscopic healing (modified Mayo endoscopy score 0 or 1). METHODS: We conducted a retrospective cohort study in adults with active ulcerative colitis (modified Mayo endoscopy score 2 or 3), whose treatment was iteratively optimised to achieve endoscopic healing. We identified predictors of achieving histologic remission, and outcomes (risk of symptomatic relapse, and ulcerative colitis-related hospitalisation and/or surgery) of achieving histologic remission vs persistent histologic activity, using Cox proportional hazard analysis. RESULTS: Of the 411 patients with clinically active ulcerative colitis, 270 achieved endoscopic healing. Of the 270 patients, 55% simultaneously achieved histologic remission. Depth of endoscopic healing at final endoscopic assessment was the only independent determinant of histologic remission (modified Mayo endoscopy score 0 vs 1: odds ratio, 0.31 [95% confidence intervals, 0.18-0.52]). Over 28 months, achieving histologic remission was associated with a lower risk of clinical relapse (1-year cumulative risk: 18.7% vs 29.5%; adjusted hazard ratio, 0.56 [0.37-0.85]), and lower risk of hospitalisation (hazard ratio, 0.44 [0.20-0.94]). The incremental benefit of achieving histologic remission was observed only in patients achieving Mayo endoscopy score 1, but not Mayo endoscopy score 0. CONCLUSIONS: In patients with active ulcerative colitis treated-to-target of endoscopic healing, 55% simultaneously achieved histologic remission. Histologic remission, particularly in patients achieving modified Mayo endoscopy score 1, was associated with favourable outcomes. Treating to a target of histologic remission over endoscopic healing requires prospective evaluation.
引用
- Jangi S, Yoon H, Dulai PS, et al. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther. 2020. PMID: 33119168. doi:10.1111/apt.16026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。